Importantly, overexpression of HuR in hepatoma cells offered resistance to pharmacological NEDDylation inhibition, while low levels of HuR sensitized cells to the treatment, suggesting that HuR levels determine the druggability of the NEDDylation pathway in HCC [224]. Here, ELAVL1 is linked to hepatocellular carcinoma.